Skip to main content

Helus Pharma Inc.

corporate_fare Company Profile

Helus Pharma Inc.

HELP·NASDAQ·Life Sciences·CIK 0001833141

Cybin Inc., operating as Helus Pharma, is a clinical-stage neuropsychiatry company that develops psychedelic-based therapeutics for mental health conditions. The company is developing CYB003, a deuterated psilocybin analog, which is currently in a phase 3 clinical trial for major depressive disorder (MDD). It is also developing CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in a phase 2 clinical trial for generalized anxiety disorders. Additionally, the company has completed a phase 1 clinical intramuscular and intravenous trial for SPL028, an injectable deuterated DMT. Other developments include SPL026 for MDD and CYB005, a phenethylamine derivative, which is in the preclinical stage for treating the central nervous system. The company also maintains a research pipeline of investigational psychedelic-based compounds. Cybin Inc. has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company's headquarters are located in Toronto, Canada.

Helus Pharma Inc. (NASDAQ:HELP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for HELP at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Helus Pharma Partners with TARA Mind to Accelerate HLP003 Phase 3 Recruitment for Veteran Mental Health
  • Cybin Inc. Strengthens Scientific Advisory Board with Biotech Luminaries
  • Cybin Inc. CEO Michael Cola Steps Down; Co-founder Eric So Appointed Interim CEO
  • White House Executive Order Boosts Psychedelic Therapy Path, Directly Benefiting Helus Pharma's Breakthrough Drug
  • Helus Pharma Appoints Dr. Ken Kramer as SVP, Medical Affairs, Strengthening Neuroscience Leadership

Financial Snapshot

Fiscal year ended March 31, 2026
Net Income
-$148M
Diluted EPS
-$4.25
Op. Cash Flow
-$133.27M
Cash & Equivalents
$157.26M
Debt / Equity
0.00×
Source: 40-F · filed 2026-06-29 · accession 0001833141-26-000046

Insider Transactions

HELP files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$10.5 -0.90% today
52-week range · as of 2026-10-27 $3.76 – $15.15
Market cap
$1.37M
Volume
1.1M (0.8× avg)
3-mo avg 1.5M
Live data · 2026-10-31 20:36 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HELP - Filings & News (Page 2)

HELP
Apr 28, 2026, 3:21 PM EDT
Filing Type: 6-K
Importance Score:
7
Helus Pharma Partners with TARA Mind to Accelerate HLP003 Phase 3 Recruitment for Veteran Mental Health
Price at Filing: $5.18
Real-time Price: $10.50 info
Change: +$5.32 (+103%) info
Market Cap: $1.369M info
Sentiment: Positive
View Wiseek Article
HELP
Apr 23, 2026, 5:16 PM EDT
Filing Type: 6-K
Importance Score:
8
Cybin Inc. Strengthens Scientific Advisory Board with Biotech Luminaries
Price at Filing: $5.80
Real-time Price: $10.50 info
Change: +$4.70 (+81%) info
Market Cap: $1.369M info
Sentiment: Positive
View Wiseek Article
HELP
Apr 20, 2026, 4:55 PM EDT
Filing Type: 6-K
Importance Score:
8
Cybin Inc. CEO Michael Cola Steps Down; Co-founder Eric So Appointed Interim CEO
Price at Filing: $5.71
Real-time Price: $10.50 info
Change: +$4.79 (+84%) info
Market Cap: $1.369M info
Sentiment: Negative
View Wiseek Article
HELP
Apr 20, 2026, 8:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
White House Executive Order Boosts Psychedelic Therapy Path, Directly Benefiting Helus Pharma's Breakthrough Drug
Price at Filing: $6.00
Real-time Price: $10.50 info
Change: +$4.50 (+75%) info
Market Cap: $1.369M info
Sentiment: Positive
View Wiseek Article
HELP
Apr 16, 2026, 10:54 AM EDT
Filing Type: 6-K
Importance Score:
7
Helus Pharma Appoints Dr. Ken Kramer as SVP, Medical Affairs, Strengthening Neuroscience Leadership
Price at Filing: $5.49
Real-time Price: $10.50 info
Change: +$5.01 (+91%) info
Market Cap: $1.369M info
Sentiment: Positive
View Wiseek Article
HELP
Mar 05, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
9
HLP004 Achieves Clinically Meaningful Efficacy in Phase 2 GAD Study, Showing 10.4-Point HAM-A Reduction
Price at Filing: $7.04
Real-time Price: $10.50 info
Change: +$3.46 (+49%) info
Market Cap: $1.369M info
Sentiment: Positive
View Wiseek Article
HELP
Feb 24, 2026, 5:17 PM EST
Filing Type: 6-K
Importance Score:
8
Helus Pharma Appoints Former Pfizer CMO Dr. Freda Lewis-Hall to Board and Scientific Advisory Chair
Price at Filing: $7.35
Real-time Price: $10.50 info
Change: +$3.15 (+43%) info
Market Cap: $1.369M info
Sentiment: Positive
View Wiseek Article
HELP
Feb 17, 2026, 5:25 PM EST
Filing Type: 6-K
Importance Score:
9
Helus Pharma's SPL026 Phase 2a MDD Trial Published in Nature Medicine, Validating NSA Platform
Price at Filing: $6.71
Real-time Price: $10.50 info
Change: +$3.79 (+56%) info
Market Cap: $1.369M info
Sentiment: Positive
View Wiseek Article
HELP
Feb 13, 2026, 7:37 AM EST
Filing Type: 6-K
Importance Score:
10
Helus Pharma Secures $175M in Registered Direct Offering, Bolstering Cash Reserves for Clinical Pipeline
Price at Filing: $6.65
Real-time Price: $10.50 info
Change: +$3.85 (+58%) info
Market Cap: $1.369M info
Sentiment: Positive
View Wiseek Article
HELP
Feb 10, 2026, 5:10 PM EST
Filing Type: 6-K
Importance Score:
8
Helus Pharma Appoints Pharma Veteran Michael Cola as CEO to Lead Commercialization Push
Price at Filing: $6.41
Real-time Price: $10.50 info
Change: +$4.09 (+64%) info
Market Cap: $1.369M info
Sentiment: Positive
View Wiseek Article
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets